Get the Stockscreener App
1.47
1.38%
0.02
Compugen Ltd stock is traded at $1.47, with a volume of 240.62K.
It is up +1.38% in the last 24 hours and down -9.82% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
See More
Previous Close:
$1.45
Open:
$1.49
24h Volume:
240.62K
Relative Volume:
0.45
Market Cap:
$122.50M
Revenue:
-
Net Income/Loss:
$1.60M
P/E Ratio:
49.00
EPS:
0.03
Net Cash Flow:
$-62.91M
1W Performance:
+21.49%
1M Performance:
-9.82%
6M Performance:
-15.03%
1Y Performance:
-22.63%
1-Day Range:
$1.435
$1.50
1-Week Range:
$1.205
$1.50
52-Week Range:
$1.13
$2.66
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.47 | 122.50M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
67,041 Shares in Compugen Ltd. (NASDAQ:CGEN) Acquired by Raymond James Financial Inc. - Defense World
Compugen (NASDAQ:CGEN) vs. Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) Financial Review - Defense World
Commonwealth Equity Services LLC Takes Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer - marketscreener.com
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline By Investing.com - Investing.com South Africa
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline - Investing.com Australia
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation? - simplywall.st
Compugen at Needham Conference: Strategic Immuno-Oncology Insights - Investing.com Australia
Compugen at Needham Conference: Strategic Immuno-Oncology Insights By Investing.com - Investing.com India
Compugen stock touches 52-week low at $1.35 amid market challenges - Investing.com Canada
Compugen stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
BeiGene stock slips on trial discontinuation (ONC:NASDAQ) - Seeking Alpha
Compugen at AI Drug Discovery Conference: Strategic Partnerships Drive Progress - Investing.com
Cancer AI Breakthrough: Compugen Takes Center Stage at 3 Elite Healthcare Forums - Stock Titan
Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts - MSN
Compugen Ltd. (NASDAQ:CGEN) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - Defense World
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
Compugen at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
Compugen at Leerink’s Global Healthcare Conference: Strategic Insights - Investing.com
Oppenheimer & Co. Inc. Raises Stock Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Earnings call transcript: Compugen Q4 2024 reveals revenue decline By Investing.com - Investing.com Australia
Compugen Ltd. to Host Earnings Call - ACCESS Newswire
Compugen (NASDAQ:CGEN) Rating Lowered to Hold at StockNews.com - Defense World
Rodman & Renshaw maintains $4 price target on Compugen stock By Investing.com - Investing.com Australia
Compugen Ltd. (NASDAQ:CGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Compugen’s 2024 Results Highlight Clinical Progress and Financial Stability - TipRanks
Earnings call transcript: Compugen Q4 2024 reveals revenue decline - Investing.com India
Rodman & Renshaw maintains $4 price target on Compugen stock - Investing.com India
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Compugen: Q4 Earnings Snapshot - CTPost
Compugen earnings missed by $0.09, revenue fell short of estimates - Investing.com South Africa
Compugen Reports 2024 Financial Results and Clinical Progress - TipRanks
Compugen: Q4 Earnings Snapshot -March 04, 2025 at 07:23 am EST - Marketscreener.com
Compugen Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:13 am EST - Marketscreener.com
Compugen reports Q4 EPS (7c) vs. 11c last year - TipRanks
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Loss $-0.07 Per Share -March 04, 2025 at 07:08 am EST - Marketscreener.com
Earnings Flash (CW9) COMPUGEN LTD. Posts Q4 Revenue $1.5M - Marketscreener.com
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Revenue $1.5M -March 04, 2025 at 07:09 am EST - Marketscreener.com
How Compugen's Cancer Immunotherapy Pipeline Is Advancing While Extending Cash Runway to 2027 - StockTitan
Cancer Immunotherapy Pioneer Compugen to Share Insights at Major Healthcare Conference - StockTitan
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference - Yahoo Finance
Compugen (CGEN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Compugen Ltd expected to post earnings of 7 cents a shareEarnings Preview - TradingView
Compugen (CGEN) Expected to Announce Earnings on Tuesday - MarketBeat
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet - Simply Wall St
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):